Prognostic Parameters of Palbociclib in HR+/HER2-Advanced Breast Cancer: A Narrative Review

被引：1
|
作者：
Wang, Wei [1 ,2 ]
Wu, Jiayi [1 ,3 ]
Chen, Keyu [1 ,3 ]
Wang, Xiaojia [1 ]
Shao, Xiying [1 ]
机构：
[1] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Med Oncol,Breast Canc, 1 Banshandong Rd, Hangzhou, Peoples R China
[2] Wenzhou Med Univ, Dept Clin Med, Wenzhou, Peoples R China
[3] Zhejiang Chinese Med Univ, Dept Clin Med, Hangzhou, Peoples R China
来源：
TECHNOLOGY IN CANCER RESEARCH & TREATMENT | 2023年 / 22卷
关键词：
breast cancer; palbociclib; CDK4; 6; inhibitor; prognostic parameters; LETROZOLE;
D O I：
10.1177/15330338231173504
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recent studies have demonstrated that the combination of Cyclin-Dependent Kinase 4/6 Inhibitor (CDK4/6i) and endocrine therapy (ET) is more effective than ET alone and significantly improves progression-free survival (PFS) and overall survival (OS) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) breast cancer (BC). Palbociclib is the first CDK4/6i approved for use, and its clinical advantages have been shown. However, 30% of patients will continue to develop secondary drug resistance. Therefore, exploring the parameters that can predict the efficacy of Palbociclib and developing a clinical prediction model is essential for evaluating the prognosis of patients.
引用
收藏
页数：9
相关论文
共 50 条
  • [31] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [32] Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
    Esther S. Kim
    Lesley J. Scott
    Targeted Oncology, 2017, 12 : 373 - 383
  • [33] A novel treatment strategy of HER2-targeted therapy in combination with Everolimus for HR+/HER2-advanced breast cancer patients with HER2 mutations
    Ma, Jing
    Li, Xuelu
    Zhang, Qianran
    Li, Ning
    Sun, Siwen
    Zhao, Shanshan
    Zhao, Zuowei
    Li, Man
    TRANSLATIONAL ONCOLOGY, 2022, 21
  • [34] Matching-Adjusted Indirect Comparison of Ribociclib Plus Fulvestrant versus Palbociclib Plus Letrozole as First-Line Treatment of HR+/HER2-Advanced Breast Cancer
    Fasching, Peter A.
    Delea, Thomas E.
    Lu, Yen-Shen
    De Boer, Richard
    Hurvitz, Sara A.
    Moynahan, Aaron
    Chandiwana, David
    Lanoue, Brad
    Hu, Huilin
    Thuerigen, Astrid
    O'Shaughnessy, Joyce
    CANCER MANAGEMENT AND RESEARCH, 2021, 13 : 8179 - 8189
  • [35] Cost-effectiveness of palbociclib plus fulvestrant as second-line therapy of women with HR+/HER2-advanced breast cancer-A Chinese healthcare system perspective
    Zhu, Wentao
    Zheng, Miaomiao
    Xia, Panpan
    Hong, Wanglong
    Ma, Guoqiang
    Shen, Aizong
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [36] Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2-Advanced Breast Cancer: Findings From a Multicountry Survey
    Cardoso, Fatima
    Rihani, Julie
    Harmer, Victoria
    Harbeck, Nadia
    Casas, Ana
    Rugo, Hope S.
    Fasching, Peter A.
    Moore, Adam
    de Courcy, Joanna
    Pathak, Purnima
    Haftchenary, Sina
    Aubel, Dawn
    Schumacher-Wulf, Eva
    ONCOLOGIST, 2023, 28 (10) : 856 - 865
  • [37] Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2-advanced breast cancer
    Zhao, Qi
    Jiang, Mingxia
    Liu, Jiaxuan
    Zhang, Mengqi
    He, Maiyue
    Zhou, Shihan
    Wang, Jiani
    Mo, Hongnan
    Lan, Bo
    Yuan, Peng
    Zhang, Pin
    Ma, Fei
    Li, Qiao
    Xu, Binghe
    CANCER BIOLOGY & MEDICINE, 2024, 21 (10) : 934 - 950
  • [38] Efficacy and Safety of Palbociclib and Fulvestrant in Japanese Patients With ER+/HER2-Advanced/Metastatic Breast Cancer
    Seki, Hirohito
    Sakurai, Takashi
    Maeda, Yuka
    Oki, Naohiko
    Aoyama, Mina
    Yamaguchi, Ryou
    Tokuda, Toshiki
    Kaburagi, Takuji
    Okumura, Takehiro
    Karahashi, Tsuyoshi
    Nakajima, Kenichiro
    Higeta, Kaori
    Shimizu, Ken
    IN VIVO, 2019, 33 (06): : 2037 - 2044
  • [39] Abemaciclib plus fulvestrant in East Asian women with HR+, HER2-advanced breast cancer: Overall survival from MONARCH 2
    Toi, Masakazu
    Huang, Chiun-Sheng
    Im, Young-Hyuck
    Sohn, Joohyuk
    Zhang, Wei
    Sakaguchi, Sachi
    Haddad, Nadine
    van Hal, Gertjan
    Sledge Jr, George W.
    CANCER SCIENCE, 2023, 114 (01) : 221 - 226
  • [40] Real-world study of patients with HR+/ HER2-metastatic breast cancer treated with palbociclib and fulvestrant
    Robert, Nicholas
    Chen, Connie
    Doan, Justin
    Venkatasetty, Divea
    Espirito, Janet L.
    Aguilar, Kathleen M.
    FUTURE ONCOLOGY, 2025, 21 (01) : 83 - 94
12345